A kit comprising: (a) a first composition comprising at least an antigen and (b) a second composition comprising at least an adjuvant that is : - a lactic acid bacterium which is Lactobacillus plantarum; or - a combination of a corticosteroid with vitamin D3, 1 α,25-dihydroxyvitamin D3 and any of cholecalciferol, 1 α,25-dihydroxy-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-22-ene-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-cholecalciferol, 1 α,25-dihydroxy-23-yne-cholecalciferol, 1 α,25-dihydroxy-16-ene-cholecalciferol, 1 α,25-dihydroxy-16-ene-23 -yne-cholecalciferol, 26,26,26,27,27,27-hexafluoro-1α-fluoro-25-hydroxy-16-ene-23-yne-chole calciferol, 26,26,26,27,27,27-hexafluoro-1 α-25-dihydroxy-16-ene-23-yne-19-nor-cholecalciferol, 26,26,26,27,27,27-hexafluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol, or 26,26,26,27,27,27-hexafluoro-1 α-fluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol; in pharmaceutically acceptable carriers that are suitable for sublingual administration, for use in a method of inducing antigen-specific tolerance via sublingual co-administration, wherein co-administration of each composition is either simultaneous or consecutive. (a) a first composition comprising at least an antigen and (b) a second composition comprising at least an adjuvant that is : - a lactic acid bacterium which is Lactobacillus plantarum; or - a combination of a corticosteroid with vitamin D3, 1 α,25-dihydroxyvitamin D3 and any of cholecalciferol, 1 α,25-dihydroxy-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-22-ene-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-cholecalciferol, 1 α,25-dihydroxy-23-yne-cholecalciferol, 1 α,25-dihydroxy-16-ene-cholecalciferol, 1 α,25-dihydroxy-16-ene-23 -yne-cholecalciferol, 26,26,26,27,27,27-hexafluoro-1α-fluoro-25-hydroxy-16-ene-23-yne-chole calciferol, 26,26,26,27,27,27-hexafluoro-1 α-25-dihydroxy-16-ene-23-yne-19-nor-cholecalciferol, 26,26,26,27,27,27-hexafluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol, or 26,26,26,27,27,27-hexafluoro-1 α-fluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol; in pharmaceutically acceptable carriers that are suitable for sublingual administration, for use in a method of inducing antigen-specific tolerance via sublingual co-administration, wherein co-administration of each composition is either simultaneous or consecutive. - a lactic acid bacterium which is Lactobacillus plantarum; or - a combination of a corticosteroid with vitamin D3, 1 α,25-dihydroxyvitamin D3 and any of cholecalciferol, 1 α,25-dihydroxy-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-22-ene-26,27-hexafluorocholecalciferol, 1 α, 25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-cholecalciferol, 1 α,25-dihydroxy-23-yne-cholecalciferol, 1 α,25-dihydroxy-16-ene-cholecalciferol, 1 α,25-dihydroxy-16-ene-23 -yne-cholecalciferol, 26,26,26,27,27,27-hexafluoro-1α-fluoro-25-hydroxy-16-ene-23-yne-chole calciferol, 26,26,26,27,27,27-hexafluoro-1 α-25-dihydroxy-16-ene-23-yne-19-nor-cholecalciferol, 26,26,26,27,27,27-hexafluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol, or 26,26,26,27,27,27-hexafluoro-1 α-fluoro-25-hydroxy-16-ene-23-yne-19-nor-cholecalciferol; in pharmaceutically acceptable carriers that are suitable for sublingual administration, for use in a method of inducing antigen-specific tolerance via sublingual co-administration, wherein co-administration of each composition is either simultaneous or consecutive. in pharmaceutically acceptable carriers that are suitable for sublingual administration, for use in a method of inducing antigen-specific tolerance via sublingual co-administration, wherein co-administration of each composition is either simultaneous or consecutive. <EOS>